Prognostic impact of the L-MCL16 assay in the validation cohort. KM curves of TTT (A) and OS (B) from diagnosis date of the nnMCL and cMCL subgroups identified by the L-MCL16 assay. KM curves of the OS from sampling date according to the presence of 17p/TP53 and/or 9p/CDKN2A alterations (C) and number of CNAs (D) for the nnMCL and cMCL subgroups. The number of CNAs was associated with OS as a continuous variable.